NCT03618537View on ClinicalTrials.gov

Ixazomib Maintenance Study in Patients With AL Amyloidosis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 2, 2018

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
AL Amyloidosis
Interventions
DRUG

Ixazomib

Ixazomib at a fixed dose of 4mg on days 1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle.

DRUG

Dexamethasone

Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue.

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

02111

Tufts Medical Center, Boston

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
collaborator

Tufts Medical Center

OTHER

collaborator

Vanderbilt University Medical Center

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03618537 - Ixazomib Maintenance Study in Patients With AL Amyloidosis | Biotech Hunter | Biotech Hunter